Health Canada authorized the Phase 1 study of mRNA-1469 as an active outbreak in the Democratic Republic of the Congo and Uganda tests how quickly vaccine platforms can move from sequence to clinical evidence
Newsflash:
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory …
Health Canada authorized the Phase 1 study of mRNA-1469 as an active outbreak in the Democratic Republic of the Congo and Uganda tests how quickly vaccine platforms can move from sequence to clinical evidence
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory …
Health Canada authorized the Phase 1 study of mRNA-1469 as an active outbreak in the Democratic Republic of the Congo and Uganda tests how quickly vaccine platforms can move from sequence to clinical evidence
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory …
LEADERS
INVESTMENTS
INNOVATION
PARTNERSHIPS
In-Depth Analysis
In-Depth Analysis
Explore our longform features and deep dives into biotech breakthroughs and innovation.
Expert Opinions
Expert Opinions
Read opinions and commentary from leading scientists, investors, and pharma leaders.
Funding & IPOs
Funding & IPOs
Track the latest funding rounds, IPO announcements, and investment trends in biotech/pharma.
Clinical Results & Milestones
Clinical Results & Milestones
Stay informed on pivotal trial results, FDA approvals, and key clinical milestones.
1
2
3
4
5
6
7
8
9
10
1
2
3
4
5
6
7
8
9
10
The Reporter Newsletter
Expert picks and exclusive deals, in your inbox.
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while combination cohorts continue
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while combination cohorts continue
Watch Now
Depot blast in Bangladesh kills nearly 50 people - BBC News
Russia accused of stealing about 600,000 tonnes of Ukraine's grain - BBC News
Devastation of Australia's climate change crisis captured on camera - BBC News
Boris Johnson survives leadership vote but 41% of his MPs have “no confidence” - BBC News
A Delaware jury awarded Yale and Biohaven $4 million after finding that Avilar Therapeutics and RA Capital willfully misappropriated a …
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, and product …
Listen Now
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while combination cohorts continue
December 18 brings a milestone for cell therapy in graft-versus-host disease—and a setback for Duchenne muscular dystrophy research, highlighting the regulatory tightrope in advanced therapeutics.
Asia-Pacific biopharma conferences in early 2025 are forging strategic partnerships, launching research initiatives, and accelerating drug development.
Starting July 31, large drugmakers face a 100 percent duty on patented medicines and active ingredients unless they secure onshoring or pricing deals with the Trump administration, and the ripple effects are already reaching contract manufacturers and clinical trial sponsors worldwide
Ready To Explore Industry News?
All articles are free -no payment or registration required.
Already a subscriber?